A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Lee, Dae Ho | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Nam, Seung Hyun | - |
dc.contributor.author | Kim, Ho Young | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Eom, Hyeon Seok | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.date.available | 2020-12-09T10:02:57Z | - |
dc.date.issued | 2009-06 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.issn | 1432-0843 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/35576 | - |
dc.description.abstract | We investigated the efficacy and toxicity of the etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx), in which oxaliplatin (Ox) was substituted for cisplatin in the ESHAP [etoposide (E), methylprednisolone (S), high-dose cytarabine (HA), and cisplatin (P)] regimen, for patients with refractory/relapsed aggressive non-Hodgkin's lymphoma (NHL). The ESHAOx consisted of E (40 mg/m(2) on days 1-4), S (500 mg on days 1-5), HA (2 g/m(2) on day 5), and Ox (130 mg/m(2) on day 1) every 3 weeks to a maximum of six cycles. Responses were assessed every three cycles. Twenty-seven patients were enrolled (19 with relapsed and 8 with refractory; 10 with an IPI score of 3-5). The overall response rate was 63% [95% confidence interval (95% CI) 45-81%], including eight complete remissions (CR) and one unconfirmed CR (33%). The median duration of response was 9.9 months (95% CI 5.7-14.2 months). After a median follow-up of 18.6 months, the median progression-free and overall survival was 5.3 months (95% CI 3.9-6.7 months) and 15.1 months (95% CI 9.4-20.9 months), respectively, with a 1-year survival rate of 61.5%. Most common grade 3/4 hematologic toxicities were neutropenia (56%) and thrombocytopenia (35%), whereas no patient experienced grade 3/4 renal or neurotoxicity. The efficacy and toxicity profiles suggested that the ESHAOx can be an alternative option for patients with refractory/relapsed aggressive NHL. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER | - |
dc.title | A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s00280-008-0847-y | - |
dc.identifier.scopusid | 2-s2.0-67349226829 | - |
dc.identifier.wosid | 000265683600003 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.64, no.1, pp 27 - 33 | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 64 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 27 | - |
dc.citation.endPage | 33 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | BONE-MARROW TRANSPLANTATION | - |
dc.subject.keywordPlus | OVARIAN-CANCER | - |
dc.subject.keywordPlus | PARMA TRIAL | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | REGIMEN | - |
dc.subject.keywordPlus | INTERMEDIATE | - |
dc.subject.keywordPlus | ORGANIZATION | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordAuthor | Lymphoma | - |
dc.subject.keywordAuthor | Salvage therapy | - |
dc.subject.keywordAuthor | Chemotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.